Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABBV with free AI briefings, catalyst countdowns, and dilution alerts.

ABBV · AbbVie Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$10.8B Cash on Hand
CF+ Cash Runway
1% Short Interest
$314.12 Analyst Target (26)
Follow ABBV by email Get an email when ABBV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABBV, unsubscribe in one click. Privacy

📣 What ABBV Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Atogepant
FDA approved Sep 2021 · Qulipta
Migraine Phase 4 · NCT06972056 Recruiting
Onabotulinumtoxina
FDA approved Dec 1991 · Botox Cosmetic
Masseter Muscle Prominence Phase 3 · NCT06068855 Completed
Upadacitinib
FDA approved Aug 2019 · Rinvoq
Hidradenitis Suppurativa Phase 3 · NCT05889182 Active not recruiting
Venetoclax
FDA approved Apr 2016 · Venclexta
Acute Myeloid Leukemia Phase 3 · NCT05183035 Active not recruiting
Telisotuzumab Vedotin
FDA approved May 2025 · Emrelis
Non Small Cell Lung Cancer Phase 3 · NCT04928846 Recruiting
Risankizumab
FDA approved Apr 2019 · Skyrizi
Psoriatic Arthritis Phase 2 · NCT06865105 Recruiting
Ubrogepant
FDA approved Dec 2019 · Ubrelvy
Healthy Volunteer Phase 1 · NCT07680686 Completed
Tavapadon
FDA approved Sep 2026 · Juvmo
Parkinson Disease N/A · NCT07158827 No longer available
Propranolol Migraine Phase 4 · NCT06972056 Recruiting
Investigator's Choice Chemotherapy Diffuse Large B-cell Lymphoma Phase 3 · NCT04628494 Active not recruiting
Fludarabine Acute Myeloid Leukemia Phase 3 · NCT05183035 Active not recruiting
Etentamig Relapsed or Refractory Multiple Myeloma Phase 3 · NCT07728188 Recruiting
ABBV-722 Systemic Sclerosis Phase 2/3 · NCT07933211 Not yet recruiting
Vincristine B-Cell Non-Hodgkin Lymphoma Phase 1/2 · NCT05201248 Active not recruiting
Bendamustine Diffuse Large B-Cell Lymphoma Phase 1/2 · NCT04663347 Active not recruiting
Zanubrutinib Chronic Lymphocytic Leukemia Phase 2 · NCT07734038 Recruiting

Also used in these trials (approved or third-party drugs, not ABBV's own candidates): Topiramate, Dexamethasone, Pomalidomide, Gemtuzumab Ozogamicin, Epcoritamab, Docetaxel Anhydrous, Daratumumab, Cytarabine, Carfilzomib, Azacitidine, Bimatoprost, Teclistamab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABBV holds $10.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABBV files for a raise →

👥 Who Owns ABBV

Insiders 0.1% Institutions (5352 holders) 77% Public and other holders 22.9%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 148,974,939 8.43% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 132,924,058 7.52% 2026-03-31
State Street Corporation Institution (13F) 82,815,387 4.69% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 49,001,331 2.77% 2026-09-30
Geode Capital Management, LLC Institution (13F) 47,503,777 2.69% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 45,333,436 2.56% 2026-09-30
Morgan Stanley Institution (13F) 38,398,732 2.17% 2026-09-30
Capital Research Global Investors Institution (13F) 31,115,872 1.76% 2026-09-30
Bank of America Corporation Institution (13F) 26,386,673 1.49% 2026-09-30
Azita Saleki-gerhardt
EVP, CHIEF OPERATIONS OFFICER · +20,312 options
Insider 204,373 0.01% 2026-02-27
Robert A. Michael
CHAIRMAN OF THE BOARD AND CEO, Director · +81,251 options
Insider 178,737 0.01% 2026-02-27
Thomas C Freyman
Director
Insider 133,810 0.01% 2026-05-08

Share count 1,767,616,306 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-12
filed 2026-11-12
Stewart Jeffrey Ryan
Gift (G) 3,450 – 79,721
2026-11-09
filed 2026-11-12
Stewart Jeffrey Ryan
Option exercise (M) 16,070 $114.36 99,241
2026-11-09
filed 2026-11-12
Stewart Jeffrey Ryan
Option exercise (M) 24,549 $93.50 123,790
2026-11-09
filed 2026-11-12
Stewart Jeffrey Ryan
Sale (S) 40,619 $293.60 83,171
2026-11-09
filed 2026-11-12
Stewart Jeffrey Ryan
Option exercise (M) 16,070 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ABBV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABBV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.